Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Cyclooxygenase-2–Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients
- A. Whelton, J. Fort, J. Puma, D. Normandin, A. Bello, K. Verburg
- MedicineAmerican Journal of Therapeutics
- 1 March 2001
Patients taking antihypertensive therapy and receiving cyclooxygenase-2–specific inhibitors should be monitored for the development of cardiorenal events.
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders:a review of the literature
A growing body of evidence provides a rationale for the use of collagen hydrolysate for patients with OA and suggests mechanisms that might help patients affected by joint disorders such as OA.
Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis
- A. Bello, E. Perkins, R. Jay, P. Efthimiou
- MedicineOpen Access Rheumatology : Research and Reviews
- 31 March 2017
To improve the response to oral MTX, a high initial dose should be administered followed by rapid titration, and this approach does not appear to compromise safety or tolerability for patients.
Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen
Tanezumab provides efficacious treatment of knee or hip OA and may have therapeutic utility in patients with OA who experience inadequate analgesia with nonsteroidal antiinflammatory drugs despite replicated favorable coprimary outcomes.
Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
There is insufficient evidence to conclude that there are significant differences between the approved NSAIDs with regard to the potential for cardiovascular events, and clinicians should continue to use the current FDA NSAID labeling language to guide their decision making for individual patients.
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
- L. Laine, A. Kivitz, A. Bello, A. Grahn, M. Schiff, A. Taha
- MedicineAmerican Journal of Gastroenterology
- 20 December 2011
Combined results of the REDUCE studies indicate that double-dose famotidine plus ib uprofen, given as a combination tablet, decreases endoscopic upper GI ulcers as compared with ibuprofen alone.
Report of the American College of Rheumatology Pain Management Task Force
Although commonly recommended, nonpharmacologic psychosocial interventions such as cognitive–behavioral therapy or body-based therapies including exercise are generally considered less effective by rheumatologists despite evidence that such approaches can be highly efficacious depending on the setting or disease.
COX-2 Specific Inhibitors in the Management of Osteoarthritis of the Knee: A Placebo-Controlled, Randomized, Double-Blind Study
- F. Mckenna, A. Weaver, J. Fiechtner, A. Bello, J. Fort
- MedicineJournal of clinical rheumatology
- 1 June 2001
Once-daily doses of celecoxib 200 mg and rofecoxib 25 mg offer comparable efficacy and are an effective alternative to conventional NSAIDs in the management of OA.